ON IMAGING PLATFORM

ON IMAGING PLATFORM

ONM-100 Addresses Unmet Need for Real-Time Cancer Resection Imaging

  • Currently, surgeons rely on relatively imprecise imaging results conducted prior to surgery to identify the general location, scope of tumor, and lymph node invasion
  • In the OR, surgeons typically rely on use of cameras, visual inspection and palpation to identify tumors, and the margin between tumor and normal tissue
  • Literature and our clinical experience indicate that the current standard of care for tumor resection can result in positive margins and satellite tumors left behind
  • ONM-100 provides surgeons with real-time, sharp visualization of tumors improving surgical outcomes
ONM-100 Clinical Success Demonstrates Precision of Micelle Technology

Key Clinical Findings:

  • Very well tolerated, no product related SAEs
  • Florescence seen across all 6 tumor types in ~45pts- Breast,Colorectal,Esophageal,Head&Neck, Ovarian, Prostate
  • Clear, real-time delineation of tumor
  • Phase 1 results:- 100%responserate(abilitytoidentifytumors)- IdentifiedoccultdiseasemissedbySOCin ~30% of patients
  • Dose proportional PK, 44±16 hr half-life
  • FDAFastTrackdesignation
ONM-300: Technology Also Employed in Next Generation PET Imaging Agent
  • IV injectable whole body non-invasive tumor imaging using 64Cu
  • Precision imaging of tumors poorly imaged by FDG-PET incl. brain
  • Eliminates false positives from brown fat, inflammation, striated muscle
And...Clinical Imaging Experience Validates Cancer Therapeutic Platforms and Associated Programs
  • IV injectable whole body non-invasive tumor imaging using 64Cu
  • Precision imaging of tumors poorly imaged by FDG-PET incl. brain
  • Eliminates false positives from brown fat, inflammation, striated muscle